Close Menu
    What's Hot

    Fujifilm UK Pension Scheme Completes Bulk Purchase Annuity Transaction With Royal London

    November 11, 2026

    Clariant Pension Plan Completes Bulk Purchase Annuity Transaction With M&G

    November 11, 2026

    Editor’s Letter – Volume 2, Issue 11, November 2026

    November 11, 2026
    X (Twitter) LinkedIn
    Longevity & Mortality Investor
    • Home
    • Coverage
      1. Life Insurance Capital Solutions
      2. Life Insurance
      3. Longevity and Mortality Risk Transfer
      4. Mortality
      5. Secondary Life Markets
      6. View All

      Symetra and TIAA Partner To Launch Mariner Re

      October 27, 2026

      Chariot Re Announces Fourth Reinsurance Transaction, First Covering Japanese Liabilities

      October 15, 2026

      Pacific Life Re Executes First Asset-Intensive Reinsurance Transaction in Hong Kong

      September 9, 2026

      Bermuda Life & Annuity Sidecar Market Quadruples as Alternative Asset Manager/Life Insurance Convergence Continues

      September 9, 2026

      Q&A: Alexandr Dudarev, CEO, Inshurik

      October 28, 2026

      Is Dementia the Next Big Longevity Event?

      October 15, 2026

      US Individual Life Insurance Sales Continue Growth Trend in the Second Quarter

      August 13, 2026

      Shaping the Future of Health Insurance Through Innovation and Analytics

      June 10, 2026

      Fujifilm UK Pension Scheme Completes Bulk Purchase Annuity Transaction With Royal London

      November 11, 2026

      Clariant Pension Plan Completes Bulk Purchase Annuity Transaction With M&G

      November 11, 2026

      Sponsor Demand Intact as US Pension Risk Transfer Market Prepares for Busy Year-End

      November 11, 2026

      Delcam Retirement Benefits Scheme Completes Bulk Purchase Annuity Transaction With Royal London

      November 5, 2026

      Record Low Mortality Rates So Far in 2026 in England and Wales, Says CMI

      October 12, 2026

      Record Low Mortality Rates So Far in England and Wales in 2026

      July 9, 2026

      Organ Transplant Improvements Test Life Expectancy Assessment Models

      July 8, 2026

      The Pursuit of Everlasting Life Unlikely to Shift Actuarial Models

      June 10, 2026

      Global Equity Release Market Participants Remain Bullish Despite Macro Headwinds

      November 11, 2026
      Litigation

      Litigation Update: Estate of Long v. Wells Fargo Bank, N.A.

      November 11, 2026

      Life Insurance Settlement Association Announces New Chair, Composition of Board for 2027

      November 11, 2026

      UK Equity Release Activity Nudges Higher in Third Quarter

      October 28, 2026

      Fujifilm UK Pension Scheme Completes Bulk Purchase Annuity Transaction With Royal London

      November 11, 2026

      Clariant Pension Plan Completes Bulk Purchase Annuity Transaction With M&G

      November 11, 2026

      Editor’s Letter – Volume 2, Issue 11, November 2026

      November 11, 2026

      Global Equity Release Market Participants Remain Bullish Despite Macro Headwinds

      November 11, 2026
    • Events
    • Latest Issues

      Editor’s Letter – Volume 2, Issue 11, November 2026

      November 11, 2026
      Life Risk News Editors Letter

      Editor’s Letter – Volume 2, Issue 10, October 2026

      October 15, 2026

      Editor’s Letter – Volume 2, Issue 9, September 2026

      September 9, 2026

      Editor’s Letter – Volume 2, Issue 8, August 2026

      August 12, 2026

      Editor’s Letter – Volume 2, Issue 7, July 2026

      July 8, 2026
    • Contact Us
    Newsletter
    Longevity & Mortality Investor

    Liver Disease Mortality in England Continues to Worsen but General Mortality Still on a Post-Covid Downward Trend

    Mortality June 12, 2025By Greg Winterton
    Share
    Twitter LinkedIn Email

    The UK government’s Department of Health and Social Care (DHSC) maintains a Mortality Profile for England, a database which provides trends in mortality rates for a wide range of causes of death in England; the main update comes in November each year, when data for the prior year becomes available. 

    A recent update from May this year, however, brings together a selection of mortality indicators which the DHSC says is designed to ‘make it easier to assess outcomes across a range of causes of death’ in England. 

    It is mostly good news for the general population; the mortality rate from all causes for all ages for both sexes fell in 2023 to 964 deaths per 100,000 people, the third lowest figure since 2001. 

    Figure 1: Mortality rate from all causes, all ages (Persons, 1 year range) 

    Fig.1

    Source: Office for Health Improvement and Disparities, Department of Health and Social Care 

    The overall numbers mask a couple of noticeable trends for mortality rates for certain diseases, however. 

    The DHSC uses a categorisation system for the trends it produces; the all-cause mortality rate above is ‘decreasing and getting better’, for example. 

    But for liver disease, mortality is ‘increasing and getting worse’. The mortality rate for those with liver disease has been on the rise for 25 years. In 2001, only 18.6 per 100,000 people died, a number that, at the end of 2023, stood at 27.7 per 100,000 for all persons, all ages.  

    A couple of factors are driving the trend. 

    “Together, alcohol, viral hepatitis, and overweight and obesity are the major causes of liver disease. Alcohol consumption patterns vary according to age, sex, and socioeconomic status; the pandemic amplified risky drinking behaviours in those already considered to be high-risk drinkers,” said Nicky Draper, Director of Life & Health Consulting at Crystallise. 

    “In addition, England has, like many other countries in the developed world, high rates of obesity and Type 2 diabetes in the population. Non-Alcoholic Fatty Liver Disease (NAFLD), which is generally brought on by poor diets, high in sugar and saturated fats, and sedentary lifestyles – can progress silently to non-alcoholic steatohepatitis (NASH) and eventually cirrhosis or liver failure, even in non-drinkers.” 

    Figure 2: Mortality rate from liver disease, all ages (Persons, 1 year range) 

    Fig.2

    Source: Office for Health Improvement and Disparities, Department of Health and Social Care 

    Combating this rise is certainly on the radar of the public health overseers. The UK Health Security Agency published a call to action back in 2021 and then towards the end of that year, the EASL–Lancet Liver Commission called for ‘a paradigm shift in European Liver Disease response’. 

    Current initiatives, then, do not seem to be going far enough. It doesn’t help that most people don’t know they’re at risk until it’s too late — liver disease is largely symptomless until advanced – and there is something of a crowding out effect impacting efforts, too. 

    “Cancer, strokes, and heart disease, for example, receive significantly more funds and awareness than liver disease does. It is unfortunate and frustrating, because it’s such a preventable disease when compared to many others,” said Draper. 

    One trend where there has been a reversal in recent years is in the respiratory disease category. Similar to the trend in the general mortality rate, respiratory disease mortality has been trending downwards – until the past three years. In 2021, 93.8 deaths per 100,000 were observed, which, at the end of 2023, was 117.8; another one for the ‘increasing and getting worse’ bucket. However, the impact of the lockdowns could have a bearing on this trend. 

    “The rates appear to go down in 2020, no doubt due to the effects of social distancing and the subsequent reduction in flu, and other respiratory illnesses at the time,” said Draper. 

    There are areas where the mortality picture in England is better. Cancer, for example, has been on a downward mortality trend for the past 25 years, and despite a blip in 2022, continued its ‘decreasing & getting better’ trajectory in 2023. And while the trend for cardiovascular disease – which, at 232.4 deaths per 100,000 in 2023 – has been plateauing recently (largely due to adverse lifestyle behaviours being on the increase, and Covid-19, both primary as in direct damage to the cardiovascular system, and secondary, the delays in healthcare), the mortality rate is not increasing at this time.  

    The bigger picture to all of this is that mortality is getting harder to predict, not easier, and one reason could be the impact of Covid-19. 

    “Some of the trends in disease mortality in England, such as in liver disease, are very consistent trends – they are gradually and consistently improving, or gradually and consistently worsening, and modelling for that, for example, is unlikely to change too much unless the government puts significant sums into preventative measures that significantly stem or reverse the decline,” said Draper. 

    “But in instances where you see trend reversals, then of course, that’s more difficult to incorporate, even into general population models. Before the Covid-19 pandemic, there was more certainty with regards to the direction of travel for many diseases. But when you have such a disruptive situation like Covid caused by a virus that is able to have such a broad effect on many body systems, I think we’re still seeing the shake-out of the impact of that, to a degree.” 

    2025 - June Clinical Mortality Mortality Risk Volume 4 Issue 6 - June 2025
    Share. Twitter LinkedIn Email

    Related Posts

    Is Dementia the Next Big Longevity Event?

    October 15, 2026By Richard Marshall and Scott Hamilton

    Organ Transplant Improvements Test Life Expectancy Assessment Models

    July 8, 2026By Mark McCord

    The Pursuit of Everlasting Life Unlikely to Shift Actuarial Models

    June 10, 2026By Mark McCord

    Shaping the Future of Health Insurance Through Innovation and Analytics

    June 10, 2026By Jessica Plewes and Lisa Balboa
    Latest Issue

    Global Equity Release Market Participants Remain Bullish Despite Macro Headwinds

    November 11, 2026
    Litigation

    Litigation Update: Estate of Long v. Wells Fargo Bank, N.A.

    November 11, 2026

    Sponsor Demand Intact as US Pension Risk Transfer Market Prepares for Busy Year-End

    November 11, 2026

    New Report Highlights Tighter Regulatory Oversight of Asset-Intensive Reinsurance

    October 28, 2026
    Ad

    Where Longevity and Mortality Meet the Markets
    ISSN 2978-5219

    X (Twitter) LinkedIn
    Coverage
    • Life Insurance Capital Solutions
    • Life Insurance
    • Longevity and Mortality Risk Transfer
    • Mortality Risk
    • Secondary Life Markets
    More Info
    • Home
    • About Us
    • Contact Us
    • Guest Articles
    • Submit Story Idea
    Our Newsletter
    Get the latest industry news, commentary and events from the Longevity & Mortality Investor directly into your inbox. Why not sign up today?

    © 2026 Longevity & Mortality Investor. Website by Kavells.
    • Sitemap
    • Privacy Policy
    • Copyright Notice
    • Terms & Conditions

    Type above and press Enter to search. Press Esc to cancel.